Each year, more than 78 million surgical patients in the U.S. are prescribed opioids to treat postsurgical pain.1 Although opioids play a critical role in pain management, the failure to implement effective stewardship of these drugs can translate into unintended and even tragic consequences.
The lives lost and the billions of dollars used to treat these issues after the fact make it clear that a new approach is needed. We offer a new solution.
PrecisionOp uses pharmacogenetics testing to deliver a personalized approach to your patients’ postoperative pain management. It is a simple tool that:
The PrecisionOp platform provides simple and safe recommendations for postoperative regimen medications based on a patient’s genetic profile, in less than 10 minutes. Our dashboard delivers a tactical medication calculator designed for surgeons and the surgical experience; a simple patient pre-op swab-test lab helps guide clinical decision support prior to the day of surgery.
With an easy to adopt, intuitive dashboard presenting highly specific information for both patient and practice, PrecisionOp takes into consideration the clinic, the procedure and the pharmacy. Our platform is even customized to your preferred medication regimens for specific procedures, and alternative medications are recommended based on safety and availability in the filling pharmacy.
Beyond a simple gene, allele and phenotype data download, PrecisonOp breaks down your patient’s metabolizer status, offering straightforward drug-gene relationship guidance that meets the highest levels of evidence from the FDA, CPIC and other governing bodies.
Of the estimated 80 million surgeries performed annually, complications from prescription mismanagement for postoperative pain contribute to ADRs, prolonged hospital stay readmissions, and overuse of opioids.1
$528 billion spent on non-optimized medication use and medication-related problems in the US alone.2
20% of patients experience adverse events within three weeks of discharge.3
Adverse drug reactions (ADRs) are the 4th leading cause of death, with approximately 1.3M ED visits of those 350K patients hospitalized.4
The PrecisionOp platform has been designed to be fully interpreted within your practice. Our straightforward and responsive dashboard is the result of years of discussions with our partnering surgeons and their care teams.
Our goal of helping you deliver a postoperative medication regimen that not only aligns with your patients’ genetic make-up, but also with your preferred postoperative therapies and medications.
PrecisionOp offers you and your team a clear, customized list of safe and available alternatives, giving you options to sub-out medications; resulting in a new regimen fully aligned with your patient’s genetics.
An IRB approved study to collect and correlate genomic data with clinical outcomes, such as ADRs, on patients 18 years and older to better predict interpatient variability of postsurgical medication response. The PRospective Outcomes Molecular Implementation Support Registry, or PROMISRx, is a translational research trial directed at improving pharmacogenomic recommendations in the diverse population of the United States and ultimately delivering on the promise of precision medicine.
180 million surgeries performed annually, complications from prescription mismanagement for postoperative pain contribute to ADRs, prolonged hospital stay, readmissions, and overuse of opioids (citation: Koepke EJ, Manning EL, Miller TE, Ganesh A, Williams DGA, Manning MW. The rising tide of opioid use and abuse: the role of the anesthesiologist. Perioper Med. 2018;7(1):1-10. doi:10.1186/s13741-018-0097-4)
2$528 billion estimated to be spent annually in the United States on drug-related morbidity and mortality resulting from nonoptimized medication therapy (citation: Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother. 2018;52(9):829-837. doi:10.1177/1060028018765159)
320% of patients experience adverse events within three weeks of discharge, with adverse drug reactions accounting for nearly two thirds of such events (citation: Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138(3):161-167. doi:10.7326/0003-4819-138-3-200302040-00007)
4Adverse drug reactions have been estimated to be as high as the 4th leading cause of death in the United States and represent a leading clinical issue in the perioperative arena (citation: Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-1205. doi:10.1001/jama.279.15.1200)